Joel Greenblatt’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $345K | Buy |
+7,422
| New | +$356K | ﹤0.01% | 1607 |
|
|
2025
Q3 | – | Sell |
-17,623
| Closed | -$555K | – | 1815 |
|
|
2025
Q2 | $555K | Sell |
17,623
-13,060
| -43% | -$419K | ﹤0.01% | 1299 |
|
|
2025
Q1 | $1M | Sell |
30,683
-8,529
| -22% | -$302K | 0.01% | 1007 |
|
|
2024
Q4 | $1.42M | Buy |
39,212
+1,419
| +4% | +$50K | 0.01% | 807 |
|
|
2024
Q3 | $1.18M | Buy |
37,793
+26,742
| +242% | +$835K | 0.01% | 879 |
|
|
2024
Q2 | $296K | Buy |
11,051
+4,046
| +58% | +$117K | ﹤0.01% | 1231 |
|
|
2024
Q1 | $239K | Buy |
+7,005
| New | +$209K | ﹤0.01% | 1248 |
|
|
2023
Q3 | – | Sell |
-8,791
| Closed | -$264K | – | 1408 |
|
|
2023
Q2 | $264K | Buy |
+8,791
| New | +$308K | 0.01% | 1158 |
|
|
2022
Q2 | – | Sell |
-10,264
| Closed | -$332K | – | 1247 |
|
|
2022
Q1 | $332K | Sell |
10,264
-1,010
| -9% | -$31K | 0.01% | 921 |
|
|
2021
Q4 | $329K | Buy |
11,274
+1,097
| +11% | +$33.3K | 0.01% | 925 |
|
|
2021
Q3 | $271K | Buy |
+10,177
| New | +$273K | 0.01% | 873 |
|
|
2020
Q3 | – | Sell |
-10,812
| Closed | -$257K | – | 1130 |
|
|
2020
Q2 | $257K | Sell |
10,812
-34,167
| -76% | -$755K | 0.01% | 896 |
|
|
2020
Q1 | $809K | Sell |
44,979
-37,468
| -45% | -$787K | 0.02% | 608 |
|
|
2019
Q4 | $1.96M | Sell |
82,447
-21,103
| -20% | -$513K | 0.04% | 476 |
|
|
2019
Q3 | $2.85M | Buy |
103,550
+4,477
| +5% | +$133K | 0.05% | 391 |
|
|
2019
Q2 | $3.28M | Buy |
99,073
+14,808
| +18% | +$507K | 0.05% | 404 |
|
|
2019
Q1 | $2.95M | Buy |
84,265
+44,913
| +114% | +$1.67M | 0.04% | 433 |
|
|
2018
Q4 | $1.31M | Buy |
39,352
+31,287
| +388% | +$1.35M | 0.02% | 578 |
|
|
2018
Q3 | $406K | Buy |
8,065
+1,689
| +26% | +$83.4K | 0.01% | 775 |
|
|
2018
Q2 | $382K | Sell |
6,376
-26,405
| -81% | -$1.37M | 0.01% | 736 |
|
|
2018
Q1 | $1.5M | Sell |
32,781
-106,816
| -77% | -$4.46M | 0.02% | 547 |
|
|
2017
Q4 | $5.56M | Sell |
139,597
-28,939
| -17% | -$1.14M | 0.08% | 337 |
|
|
2017
Q3 | $6.74M | Buy |
168,536
+144,155
| +591% | +$6.24M | 0.1% | 305 |
|
|
2017
Q2 | $1.05M | Sell |
24,381
-77,620
| -76% | -$2.76M | 0.01% | 633 |
|
|
2017
Q1 | $3.19M | Buy |
+102,001
| New | +$2.73M | 0.04% | 474 |
|
|
2016
Q3 | – | Sell |
-12,455
| Closed | -$254K | – | 1038 |
|
|
2016
Q2 | $254K | Sell |
12,455
-5,097
| -29% | -$90.4K | ﹤0.01% | 844 |
|
|
2016
Q1 | $268K | Sell |
17,552
-16,256
| -48% | -$212K | ﹤0.01% | 861 |
|
|
2015
Q4 | $454K | Sell |
33,808
-5,334
| -14% | -$82.5K | ﹤0.01% | 707 |
|
|
2015
Q3 | $549K | Sell |
39,142
-49,125
| -56% | -$913K | 0.01% | 710 |
|
|
2015
Q2 | $1.5M | Buy |
88,267
+46,581
| +112% | +$663K | 0.01% | 578 |
|
|
2015
Q1 | $504K | Buy |
+41,686
| New | +$394K | ﹤0.01% | 693 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Joel Greenblatt's SUPN Position: Q2 2026 in Review
Joel Greenblatt opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 7,422 shares worth $345K. The stake represents ﹤0.01% of the portfolio and ranks #1607 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in SUPN as recently as Q2 2025.
Joel Greenblatt first reported a position in SUPN in Q1 2015 and has held it in 31 quarters since. The position peaked at $6.74M in Q3 2017. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Joel Greenblatt held 7,422 shares of Supernus Pharmaceuticals worth $345K as of Q2 2026.
- Supernus Pharmaceuticals was a new Joel Greenblatt position in Q2 2026.
- Supernus Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1607 holding.
- Joel Greenblatt first reported a position in Supernus Pharmaceuticals in Q1 2015 and has held it in 31 quarters since.
- Joel Greenblatt's Supernus Pharmaceuticals position peaked at $6.74M in Q3 2017.
- 331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.